Clinical Trials in Arizona

Showing 2421-2440 of 8,032 trials

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219

This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.

Solid Tumor, Adult

Adanate, Inc46 participantsStarted Nov 2022

Scottsdale, Arizona, United States • Orlando, Florida, United States • Durham, North Carolina, United States +2 more locations

COMPLETEDPhase 131 miles

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

NCT05775406

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, myelofibrosis, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) (MTD) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.

Myeloid MalignanciesAcute Lymphocytic LeukemiaLymphomas+1 more

Kymera Therapeutics, Inc.52 participantsStarted May 2023

Scottsdale, Arizona, United States • Sacramento, California, United States • Boston, Massachusetts, United States +8 more locations

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Find Trials by Condition in Arizona

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Novel Experimental COVID-19 Therapies Affecting Host Response

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

CLUSTER Trial for Outbreak Detection and Response

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

Intermediate-Size Expanded Access Protocol (EAP) for LP352

International EXPAND Heart Pivotal Trial

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma

Non-Complex Biliary Stones DSC vs ERC

Plasma Resuscitation Without Lung Injury

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)